K36 Therapeutics, Inc., a US-based clinical-stage biotech company, announced on Wednesday that it has named Benjamin Winograd, MD, PhD as its new chief medical officer to head the Medical and Clinical teams.

In the new role, Dr Winograd will head clinical development, translational medicine, regulatory affairs, and medical affairs.

Dr Winograd has served as vice president of Clinical Development and head of Clinical Haematology/Oncology at Celgene. He has served in roles of increasing responsibility at Schering Plough, Pharmacia and BMS. He has also served as the chief medical officer at Lava Therapeutics. He has more than 30 years of industry experience.